SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy
2024

SON-1010: A New Cancer Treatment Using IL-12

Sample size: 36 publication 10 minutes Evidence: high

Author Information

Author(s): Cini John K., Kenney Richard T., Dexter Susan, McAndrew Stephen J., Eraslan Rukiye-Nazan, Brody Rich, Rezac Darrel J., Boohaker Rebecca, Lapi Suzanne E., Mohan Pankaj

Primary Institution: Sonnet BioTherapeutics, Inc.

Hypothesis

Can an albumin-binding IL-12 fusion protein improve cytokine half-life, target tumors, and enhance therapeutic efficacy?

Conclusion

SON-1010 effectively targets tumors and has a prolonged half-life, enhancing its therapeutic efficacy.

Supporting Evidence

  • SON-1010 showed a 4-fold increase in half-life compared to standard IL-12.
  • Significant tumor growth inhibition was observed in treated mice.
  • SON-1010 demonstrated enhanced immune response with increased IFNγ production.
  • Safety and efficacy are being studied in ongoing clinical trials.

Takeaway

Scientists created a new medicine called SON-1010 that helps fight cancer by making a special protein last longer in the body and go directly to the tumors.

Methodology

The study involved developing a fusion protein that links IL-12 to an albumin-binding domain, followed by preclinical testing in mouse models.

Potential Biases

Potential bias due to funding from Sonnet BioTherapeutics, Inc.

Limitations

The study primarily focused on mouse models, which may not fully predict human responses.

Participant Demographics

C57BL/6 female mice were used in the study.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1493257

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication